Posts
May 23 2023
NovaBay Pharmaceuticals, Inc. announced the closing of its Private Placement offering in the amount of $3,000,000. EG&S acted as counsel to the Placement Agent.
May 23 2023 Event
Family Leave and Providing Reasonable Accommodation in NYC
Join the Labor & Employment Lawyers from Ellenoff Grossman & Schole LLP for an in-person complimentary breakfast event where we will review Family Leave and Providing Reasonable Accommodations in New York City and earn CLE credits.
Click here to register.
May 23 2023 Event
Quarterly Hospitality Roundtable: “What’s the next challenge?”
There are always new obstacles, trends, regulations, and emerging risks that restaurants and other hospitality businesses must adapt to and prepare for in order to achieve continued recovery and future success. Please join a panel of experts from Ellenoff Grossman & Schole LLP, HUB International, the New York State Restaurant Association, Marcum LLP and Total Food Service magazine for our next must-attend, informative hospitality industry seminar, where they will address the most frequently asked questions, issues, and concerns on timely topics impacting the industry.
Click here to register.
May 22 2023
Microbot Medical Inc. announced the closing of its Registered Direct offering in the amount of $1,400,000. EG&S acted as counsel to the Placement Agent.
May 19 2023
Baudax Bio, Inc. announced the closing of its Public Offering in the amount of $4,000,000. EG&S acted as counsel to the Placement Agent.
May 17 2023
Biodexa Pharmaceuticals PLC announced the closing of its Registered Direct offering in the amount of $3,320,000. EG&S acted as counsel to the Placement Agent.
May 17 2023
SunCar Technology Group Inc., a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation service in China, announced the completion of the previously announced business combination with Goldenbridge Acquisition Limited, a publicly traded special purpose acquisition company. EGS acted as counsel to Maxim Group LLC, the M&A and financial advisor to Goldenbridge.
May 17 2023
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced the pricing of its registered direct offering in the amount of $4,000,000. EGS acted as counsel to Maxim Group LLC, the sole placement agent for the offering.